Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Roelcke

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
World Neurosurgery|August 26, 2018
Longitudinal Imaging of Tumor Volume, Diffusivity, and Perfusion After Preoperative Endovascular Embolization in Supratentorial Hemispheric MeningiomasPhilipp Gruber, Lucia Schwyzer, Elisabeth Klinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2002
PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomasUlrich Roelcke, Oliver Hausmann, Adrian Merlo, et al.
Swiss Medical Weekly|June 20, 2020
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adultsPatrick Roth, Andreas F Hottinger, Thomas Hundsberger, et al.
Neuro-Oncology Practice|March 18, 2024
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and olderChristina Stadler, Dorothee Gramatzki, Emilie Le Rhun, et al.
Acta Oncologica (Stockholm, Sweden)|April 19, 2011
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trialsSilvia Hofer, Katarzyna Elandt, Richard Greil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
MRI and <sup>18</sup>FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE TrialHans-Georg Wirsching, Ulrich Roelcke, Jonathan Weller, et al.
Neuro-Oncology|September 11, 2015
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningiomaJulia Furtner, Veronika Schöpf, Katharina Seystahl, et al.
Neuro-Oncology|August 8, 2018
Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progressionRaymond Y Huang, Prashin Unadkat, Wenya Linda Bi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2016
Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor MimicMarkus Hutterer, Yvonne Ebner, Markus J Riemenschneider, et al.
Swiss Medical Weekly|May 17, 2021
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)Silvia Hofer, Kristina Keller, Lukas Imbach, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
World Neurosurgery|August 26, 2018
Longitudinal Imaging of Tumor Volume, Diffusivity, and Perfusion After Preoperative Endovascular Embolization in Supratentorial Hemispheric MeningiomasPhilipp Gruber, Lucia Schwyzer, Elisabeth Klinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2002
PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomasUlrich Roelcke, Oliver Hausmann, Adrian Merlo, et al.
Swiss Medical Weekly|June 20, 2020
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adultsPatrick Roth, Andreas F Hottinger, Thomas Hundsberger, et al.
Neuro-Oncology Practice|March 18, 2024
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and olderChristina Stadler, Dorothee Gramatzki, Emilie Le Rhun, et al.
Acta Oncologica (Stockholm, Sweden)|April 19, 2011
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trialsSilvia Hofer, Katarzyna Elandt, Richard Greil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
MRI and <sup>18</sup>FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE TrialHans-Georg Wirsching, Ulrich Roelcke, Jonathan Weller, et al.
Neuro-Oncology|September 11, 2015
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningiomaJulia Furtner, Veronika Schöpf, Katharina Seystahl, et al.
Neuro-Oncology|August 8, 2018
Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progressionRaymond Y Huang, Prashin Unadkat, Wenya Linda Bi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2016
Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor MimicMarkus Hutterer, Yvonne Ebner, Markus J Riemenschneider, et al.
Swiss Medical Weekly|May 17, 2021
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)Silvia Hofer, Kristina Keller, Lukas Imbach, et al.
Pageof 3